First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics

被引：1
|
作者：
Shapiro, G. I. [1 ]
Molina, J. [2 ]
Bendell, J. [3 ]
Brana, I. [4 ]
Spicer, J. [5 ]
Kwak, E. [6 ]
Pandya, S. [7 ]
Millham, R. [8 ]
Houk, B. [9 ]
Bell-McGuinn, K. [10 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin, Rochester, MN USA
[3] Sarah Cannon Canc Res Inst, Nashville, TN USA
[4] Val dHebron Hosp, Barcelona, Spain
[5] Guys Hosp, London SE1 9RT, England
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[8] Pfizer Oncol, NIA, New London, CT USA
[9] Pfizer Oncol, NIA, La Jolla, CA USA
[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72094-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [1] First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
    Shapiro, Geoffrey I.
    Bell-McGuinn, Katherine M.
    Molina, Julian R.
    Bendell, Johanna
    Spicer, James
    Kwak, Eunice L.
    Pandya, Susan S.
    Millham, Robert
    Borzillo, Gary
    Pierce, Kristen J.
    Han, Lixin
    Houk, Brett E.
    Gallo, Jorge D.
    Alsina, Maria
    Brana, Irene
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2015, 21 (08) : 1888 - 1895
  • [2] First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics
    Britten, C. D.
    Adjei, A. A.
    Millham, R.
    Houk, B.
    Wainberg, Z. A.
    Guthrie, T.
    Dy, G.
    LoRusso, P. M.
    EJC SUPPLEMENTS, 2010, 8 (07): : 121 - 122
  • [3] Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
    Leiker, A.
    DeGraff, W.
    Choudhuri, R.
    Sowers, A. L.
    Thetford, A.
    Cook, J. A.
    Van Waes, C.
    Mitchell, J. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S196 - S197
  • [4] Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
    Leiker, Andrew J.
    DeGraff, William
    Choudhuri, Rajani
    Sowers, Anastasia L.
    Thetford, Angela
    Cook, John A.
    Van Waes, Carter
    Mitchell, James B.
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2792 - 2801
  • [5] Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
    Wainberg, Zev A.
    Shapiro, Geoffrey
    Curigliano, Giuseppe
    Leong, Stephen
    Kristeleit, Rebecca Sophie
    Maqueda, Maria Alsina
    Britten, Carolyn D.
    Milella, Michele
    Middleton, Mark R.
    Olszanski, Anthony J.
    Vaishampayan, Ulka N.
    Lopez-Martin, Jose A.
    Gelmon, Karen A.
    Brega, Nicoletta
    Pierce, Kristen J.
    Perea, Rachelle
    Houk, Brett Edward
    Pathan, Nuzhat
    Gollerkeri, Ashwin
    Razak, Albiruni R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib
    Wainberg, Zev A.
    Shapiro, Geoffrey
    Curigliano, Giuseppe
    Kristeleit, Rebecca Sophie
    Leong, Stephen
    Alsina, Maria
    Milella, Michele
    Britten, Carolyn D.
    Gelmon, Karen A.
    Olszanski, Anthony J.
    Vaishampayan, Ulka N.
    Lopez-Martin, Jose A.
    Kern, Kenneth Alan
    Pierce, Kristen J.
    Perea, Rachelle
    Houk, Brett
    Pathan, Nuzhat
    Razak, Albiruni R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Discovery of PF-05212384/PKI-587: A phase 2 clinical PI3K/mTOR inhibitor
    Dehnhardt, Christoph M.
    Venkatesan, Aranapkam M.
    Delos Santos, Efren
    Kaloustian, Semiramis Ayral
    Broojimans, Natasja
    Hollander, Irwin
    Chen, Zecheng
    Lucas, Judy
    Mallon, Robert
    Verheijen, Jeroen
    Zask, Arie
    Khafizofa, Gulnaz
    Bursavich, Matt
    Richard, David
    Mansour, Tarek
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [8] Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
    Simon P. Langdon
    Charlene Kay
    In Hwa Um
    Michael Dodds
    Morwenna Muir
    Grant Sellar
    Julie Kan
    Charlie Gourley
    David J. Harrison
    Scientific Reports, 9
  • [9] Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
    Langdon, Simon P.
    Kay, Charlene
    Um, In Hwa
    Dodds, Michael
    Muir, Morwenna
    Sellar, Grant
    Kan, Julie
    Gourley, Charlie
    Harrison, David J.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [10] Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
    Britten, Carolyn D.
    Adjei, Alex A.
    Millham, Robert
    Houk, Brett E.
    Borzillo, Gary
    Pierce, Kristen
    Wainberg, Zev A.
    LoRusso, Patricia M.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 510 - 517
12345